0
Aldeyra Therapeutics, Inc. Banner Image

Aldeyra Therapeutics, Inc. has reached its limit for free report views

Work for Aldeyra Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Aldeyra Therapeutics, Inc.

  • Ticker ALDX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aldeyra Therapeutics, Inc. Logo Image
  • 1-10 Employees
  • Based in Lexington, Massacusetts
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release viaMore activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Aldeyra Therapeutics, Inc.

Most Recent Annual Report

Aldeyra Therapeutics, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Aldeyra Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports